Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 876

1.

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.

Feng R, Ma H, Hassig CA, Payne JE, Smith ND, Mapara MY, Hager JH, Lentzsch S.

Mol Cancer Ther. 2008 Jun;7(6):1494-505. doi: 10.1158/1535-7163.MCT-08-0183.

3.

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.

Hassig CA, Symons KT, Guo X, Nguyen PM, Annable T, Wash PL, Payne JE, Jenkins DA, Bonnefous C, Trotter C, Wang Y, Anzola JV, Milkova EL, Hoffman TZ, Dozier SJ, Wiley BM, Saven A, Malecha JW, Davis RL, Muhammad J, Shiau AK, Noble SA, Rao TS, Smith ND, Hager JH.

Mol Cancer Ther. 2008 May;7(5):1054-65. doi: 10.1158/1535-7163.MCT-07-2347.

4.
5.

Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor.

Payne JE, Bonnefous C, Hassig CA, Symons KT, Guo X, Nguyen PM, Annable T, Wash PL, Hoffman TZ, Rao TS, Shiau AK, Malecha JW, Noble SA, Hager JH, Smith ND.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6093-6. doi: 10.1016/j.bmcl.2008.10.029. Epub 2008 Oct 11.

PMID:
18954983
6.
7.

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

Maiso P, Carvajal-Vergara X, Ocio EM, López-Pérez R, Mateo G, Gutiérrez N, Atadja P, Pandiella A, San Miguel JF.

Cancer Res. 2006 Jun 1;66(11):5781-9.

9.

Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.

Sonnemann J, Dreyer L, Hartwig M, Palani CD, Hong le TT, Klier U, Bröker B, Völker U, Beck JF.

J Cancer Res Clin Oncol. 2007 Nov;133(11):847-58. Epub 2007 May 8.

PMID:
17486365
10.

SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.

Emanuele S, Lauricella M, Carlisi D, Vassallo B, D'Anneo A, Di Fazio P, Vento R, Tesoriere G.

Apoptosis. 2007 Jul;12(7):1327-38.

PMID:
17351739
11.

The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.

Mandl-Weber S, Meinel FG, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P.

Br J Haematol. 2010 May;149(4):518-28. doi: 10.1111/j.1365-2141.2010.08124.x. Epub 2010 Mar 1.

PMID:
20201941
14.

Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.

Sonnemann J, Kumar KS, Heesch S, Müller C, Hartwig C, Maass M, Bader P, Beck JF.

Int J Oncol. 2006 Mar;28(3):755-66.

PMID:
16465382
15.

Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.

Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK.

Int J Mol Med. 2005 Dec;16(6):1125-38.

PMID:
16273296
16.

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.

Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O.

Eur J Haematol. 2008 Feb;80(2):133-42. Epub 2007 Dec 20.

PMID:
18005386
18.
19.

Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells.

Gu H, Chen X, Gao G, Dong H.

Mol Cancer Ther. 2008 Aug;7(8):2298-307. doi: 10.1158/1535-7163.MCT-08-0186.

20.

The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.

Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, Czarnik AC, Payne SG, Spiegel S, Grant S.

Cancer Res. 2004 Apr 1;64(7):2590-600.

Supplemental Content

Support Center